MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
EVO

EVO

Evotec SE

$1.6
-0.07
 (-4.19%)
Exchange:  NASDAQ
Market Cap:  568.384M
Shares Outstanding:  156546
Delayed data
Calculate EVO Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – Specialty & GenericView industry performance
   
CEO:  Christian Wojczewski
Full Time Employees:  4553
Address: 
Essener Bogen 7
Hamburg
HA
22419
DE
Website:  https://www.evotec.com
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women’s health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
EVEVO logoEVOEvotec SE568.4M——-9.6%
AQAQST logoAQSTAquestive Therapeutics, Inc.578.4M——-45.3%
GLGLAS logoGLASGlass House Brands Inc614.0M——-14.4%
EOEOLS logoEOLSEvolus, Inc.517.6M—41.4-15.3%
KMKMDA logoKMDAKamada Ltd.510.6M20.719.26.9%
TLTLRY logoTLRYTilray Brands, Inc.446.2M——-3.0%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/06 — 1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue781,426796,967757,258.040
Gross Profit175,051114,88162,662.270
EBITDA24,125-80,660-13,891.224
Operating Income-47,507-142,522-135,312.161
Net Income-83,913-196,078-99,431.462

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets2,252,4681,912,5021,777,996.953
Total Liabilities1,132,560959,977964,639.269
Total Stockholders Equity1,119,908952,525813,357.682
Total Debt626,198443,538447,498.460
Cash and Cash Equivalents510,908306,387418,338.876

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow36,43918,220-9,064.546
Capital Expenditure-215,998-132,237-69,678.961
Free Cash Flow-179,559-114,017-78,743.508
Net Income-83,913-196,078-99,431.462
Net Change in Cash95,754-204,522148,315.709

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)859,630.157Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)998,174.999Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)895,348.246Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)224,390.373Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)240,763.439Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)228,611.672Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)72,771.571Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)88,213.777Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)76,752.876Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)171,056.885Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)198,625.775Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)178,164.389Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0.220Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0.250Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.200Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
844.812M  ?P/S
 (TTM)
: 
0.73
?Net Income
 (TTM)
: 
-90719653.59  ?P/E
 (TTM)
: 
-2.68
?Enterprise Value
 (TTM)
: 
654.686M  ?EV/FCF
 (TTM)
: 
-4.04
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-26.46%  ?ROIC
 (TTM)
: 
-9.58%
?Net Debt
 (TTM)
: 
186.131M  ?Debt/Equity
 (TTM)
: 
0.71
?P/B
 (TTM)
: 
0.79  ?Current Ratio
 (TTM)
: 
2.33

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about EVO valuation

Is Evotec SE (EVO) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Evotec SE (EVO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is EVO a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether EVO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is EVO’s P/E ratio?

You can see EVO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for EVO?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is EVO a good long-term investment?

Whether EVO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

EVO

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-4.19
MARKETSnap

Trading Metrics:

Open: 1.74   Previous Close: 1.67
Day Low: 1.57   Day High: 1.74
Year Low: 1.57   Year High: 4.27
Price Avg 50: 1.96   Price Avg 200: 2.78
Volume: 1.378M   Average Volume: 53296

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
08-09-2026 17:43
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
02-09-2026 03:00
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
30-06-2026 02:16
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
Evotec SE Successfully Placed €116.1 Million Convertible Bonds
12-05-2026 17:15
Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Evotec Receives Grants to Advance Tuberculosis Treatment
30-04-2026 03:20
Evotec Receives Grants to Advance Tuberculosis Treatment
Evotec Announces New Nomination to Board of Directors
29-04-2026 16:45
Evotec Announces New Nomination to Board of Directors

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • Learn
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read